“In Q1, we made decisive progress across clinical operations and R&D,” said Punit Dhillon, President & CEO of Skye. “Nimacimab continues to demonstrate a differentiated profile as a potential weight loss therapy, with a peripherally restricted mechanism that may set it apart from both GLP-1s and small-molecule CB1 inhibitors. We’re advancing a body of preclinical and clinical evidence that supports its potential in reshaping the treatment landscape in obesity.”
Easter Sale - 70% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SKYE:
- Skye Bioscience announces inducement grant under Nasdaq listing rule
- Skye Bioscience announces new preclinical data for nimacimab
- Skye Bioscience’s Positive Earnings Call Highlights Nimacimab Progress
- Skye Bioscience: Strategic Advancements and Robust Financial Health Support Buy Rating
- Skye Bioscience price target lowered to $14 from $18 at Craig-Hallum